Patient satisfaction with finasteride in the treatment of symptomatic benign prostatic hyperplasia

被引:7
|
作者
Kaplan, SA
Olsson, CA
机构
[1] Columbia-Presbyterian Medical Center, New York, NY
[2] Columbia-Presbyterian Medical Center, New York, NY 10032, 622 W. 168th St.
关键词
D O I
10.1016/S0149-2918(96)80180-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The type and magnitude of urinary symptoms, the behavioral adjustments necessitated by such symptoms, and the degree of patient satisfaction with treatment and current health were evaluated in 102 men with symptomatic benign prostatic hyperplasia (BPH) who had been receiving finasteride for 9 to 12 months. We also evaluated these variables in a group of 109 men who had under one transurethral resection of the prostate (TURF) for symptomatic BPH 9 to 12 months before the study. A validated, patient-directed telephone questionnaire was used to solicit information. Men with BPH who continued to receive finasteride therapy for at least 9 months experienced considerable symptomatic relief during the first year of therapy, and reported a high degree of satisfaction with their urinary condition. Urinary symptoms either resolved or occurred only rarely in the majority of men treated with finasteride. Most of the BPH patients taking finasteride (78%) indicated that urinary symptoms did not restrict their participation in normal activities. Fifty-four percent of finasteride patients rated their current health as excellent or very good, and 87% indicated that their current condition represented an improvement over their pretreatment state. Responses in the men treated with TURF reinforced previous observations about the effectiveness of this treatment in men with symptomatic BPH. Thus in the appropriate patient group, finasteride represents an effective management option for symptomatic BPH.
引用
收藏
页码:73 / 83
页数:11
相关论文
共 50 条
  • [31] Benign Prostatic hyperplasia How effective is Finasteride?
    Gratzke, Christian
    AKTUELLE UROLOGIE, 2011, 42 (02) : 79 - 81
  • [32] Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia - Reply
    Marks, LS
    Partin, AW
    Gormley, GJ
    Dorey, FJ
    Shery, ED
    Garris, JB
    Subong, ENP
    Stoner, E
    deKemion, JB
    JOURNAL OF UROLOGY, 1998, 160 (01): : 134 - 134
  • [33] THOUGHTS ON FINASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA - REPLY
    ROSE, LI
    HASINSKI, S
    AMERICAN FAMILY PHYSICIAN, 1993, 48 (04) : 588 - 588
  • [34] ONE-YEAR EXPERIENCE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE
    GORMLEY, GJ
    BRACKEN, B
    GELLER, J
    MCGINLEY, JI
    VAUGHAN, D
    STONER, E
    MOORE, E
    GREGG, H
    JOURNAL OF ANDROLOGY, 1991, 12 (06): : 372 - 375
  • [35] SCANDINAVIAN CLINICAL-STUDY OF FINASTERIDE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
    BEISLAND, HO
    BINKOWITZ, B
    BREKKAN, E
    EKMAN, P
    KONTTURI, M
    LEHTONEN, T
    LUNDMO, P
    PAPPAS, F
    ROUND, E
    SHAPIRO, D
    STONER, E
    SWARTZ, R
    VARENHORST, E
    EUROPEAN UROLOGY, 1992, 22 (04) : 271 - 277
  • [36] A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia
    Ekman, P
    DRUG SAFETY, 1998, 18 (03) : 161 - 170
  • [37] A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia
    Peter Ekman
    Drug Safety, 1998, 18 : 161 - 170
  • [38] Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia
    Carlin, BI
    Bodner, DR
    Spirnak, JP
    Resnick, MI
    PROSTATE, 1997, 31 (03): : 180 - 182
  • [39] SPECIFIC ANTIGEN PROSTATIC CHANGES DURING TREATMENT WITH FINASTERIDE OR DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA
    Arena, F.
    MINERVA UROLOGICA E NEFROLOGICA, 2013, 65 (03) : 211 - 216
  • [40] Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia
    Girman, CJ
    Kolman, C
    Liss, CL
    Bolognese, JA
    Binkowitz, BS
    Stoner, E
    PROSTATE, 1996, 29 (02): : 83 - 90